Swedish Registry Data Links Rituximab to Elevated Inflammatory Bowel Disease Risk in Relapsing-Remitting Multiple Sclerosis
A new Swedish population-based cohort study published in JAMA Neurology reveals that anti-CD20 treatment in multiple sclerosis is associated with a significantly higher risk of inflammatory bowel disease compared to other modern disease-modifying therapies. The investigation analyzed thousands of patient therapy episodes tracked through national registries between 2011 and 2023.
Decoding the Clinical Implications for MS Management
- The Core Finding: Rituximab therapy showed an increased incidence of new-onset inflammatory bowel disease (IBD) compared against other modern multiple sclerosis (MS) disease-modifying therapies (DMTs) such as natalizumab, dimethyl fumarate, and fingolimod.
Cohort Design, Incidence Rates, and Comparative Hazards
Led by Kallin and colleagues, the study used comprehensive data from the Swedish MS register. Researchers identified therapy initiations between January 2011 and December 2023 among individuals aged 18 to 55 years diagnosed with relapsing-remitting multiple sclerosis (RRMS) who had no previous history of inflammatory bowel disease. These therapy episodes were subsequently matched with general population comparator episodes.
The analysis encompassed a total of 13,748 therapy episodes, which broke down into 6,481 for rituximab, 2,976 for natalizumab, 2,767 for dimethyl fumarate, and 1,524 for fingolimod across 9,251 individuals. An additional 61,065 general population episodes served as a baseline benchmark. New-onset IBD was strictly defined as two or more clinical records on separate dates documenting Crohn disease, ulcerative colitis, or indeterminate colitis.
| Exposure Group | Analyzed Therapy Episodes | Observed IBD Events | Crude Incidence Rate (per 100,000 Person-Years) |
|---|---|---|---|
| Rituximab | 6,481 | 40 | 110 (95% CI: 76–147) |
| General Population | 61,065 | 120 | 41 (95% CI: 34–48) |
As detailed in PubMed coverage of the findings, the crude incidence rate of IBD reached 110 per 100,000 person-years for rituximab. Following multivariable adjustment for demographic factors and baseline multiple sclerosis characteristics, the hazard ratio for comparator DMTs versus rituximab landed at 0.10. The number needed to harm for rituximab versus comparator DMTs was calculated at 131 at the five-year mark.
Diagnostic Patterns and Treatment Discontinuations
The clinical presentation of inflammatory bowel disease following anti-CD20 exposure exhibited distinct phenotypic distributions. Crohn disease accounted for 62% of the IBD events observed within the rituximab cohort. By comparison, Crohn disease represented only 29% of IBD events recorded in the matched general population.
The burden of gastrointestinal toxicity frequently impacted therapeutic continuity.
Contraindications and When to Consult a Doctor
Because the underlying design of this registry-based investigation is purely observational, direct biological causality cannot be definitively proven.
Future Treatment Considerations in Neurological Practice
References
- Kallin S, et al. Risk of inflammatory bowel disease after anti-CD20 treatment in multiple sclerosis. JAMA Neurol. 2026;DOI:10.1001/jamaneurol.2026.3439.
- Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in Multiple Sclerosis. PubMed. PMID: 42911175.
- University of Southern California Study Finds No Benefit for Memory and Brain Aging from 2,000 milligrams of DHA
- AMC organise journées de sensibilisation
- Radiotherapy Yields Favourable Local Disease Control in Extrahepatic Bile Duct Cancer (archyworldys.com)
- MCE Announces Increased Electricity Bill Credits Through March 2027 (news-usa.today)
